Transform Wealth LLC Invests $2.48 Million in Gilead Sciences, Inc. (NASDAQ:GILD)

Transform Wealth LLC acquired a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 22,137 shares of the biopharmaceutical company's stock, valued at approximately $2,480,000.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. FMR LLC increased its holdings in Gilead Sciences by 21.6% in the 4th quarter. FMR LLC now owns 40,319,432 shares of the biopharmaceutical company's stock valued at $3,724,306,000 after buying an additional 7,157,113 shares during the period. Wellington Management Group LLP lifted its stake in Gilead Sciences by 3.1% during the fourth quarter. Wellington Management Group LLP now owns 35,659,007 shares of the biopharmaceutical company's stock worth $3,293,822,000 after purchasing an additional 1,058,331 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Gilead Sciences by 2.7% in the 4th quarter. Geode Capital Management LLC now owns 28,289,917 shares of the biopharmaceutical company's stock valued at $2,608,337,000 after purchasing an additional 749,047 shares in the last quarter. Norges Bank bought a new position in shares of Gilead Sciences in the 4th quarter valued at $1,789,254,000. Finally, Northern Trust Corp raised its holdings in shares of Gilead Sciences by 19.7% during the 4th quarter. Northern Trust Corp now owns 14,915,095 shares of the biopharmaceutical company's stock worth $1,377,707,000 after buying an additional 2,458,954 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company's stock.

Insider Activity

In other Gilead Sciences news, insider Johanna Mercier sold 28,000 shares of the company's stock in a transaction on Thursday, May 22nd. The shares were sold at an average price of $107.52, for a total transaction of $3,010,560.00. Following the transaction, the insider now owns 121,152 shares in the company, valued at approximately $13,026,263.04. This represents a 18.77% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction dated Tuesday, April 15th. The shares were sold at an average price of $106.40, for a total transaction of $266,000.00. Following the transaction, the chief financial officer now owns 168,174 shares of the company's stock, valued at $17,893,713.60. This represents a 1.46% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 43,000 shares of company stock worth $4,630,310 over the last quarter. 0.27% of the stock is currently owned by corporate insiders.

Gilead Sciences Stock Up 1.2%

Shares of Gilead Sciences stock traded up $1.33 during trading on Thursday, reaching $110.63. 2,463,231 shares of the company traded hands, compared to its average volume of 7,720,899. The firm has a market capitalization of $137.62 billion, a PE ratio of 299.00, a P/E/G ratio of 0.71 and a beta of 0.29. Gilead Sciences, Inc. has a 1-year low of $62.69 and a 1-year high of $119.96. The company has a 50 day moving average price of $105.40 and a 200-day moving average price of $101.91. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share for the quarter, beating the consensus estimate of $1.77 by $0.04. The firm had revenue of $6.67 billion for the quarter, compared to analyst estimates of $6.77 billion. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. The business's quarterly revenue was down .3% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($1.32) earnings per share. As a group, equities research analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 27th. Stockholders of record on Friday, June 13th will be issued a dividend of $0.79 per share. The ex-dividend date of this dividend is Friday, June 13th. This represents a $3.16 annualized dividend and a dividend yield of 2.86%. Gilead Sciences's dividend payout ratio is 66.53%.

Analyst Ratings Changes

Several brokerages have commented on GILD. Bank of America boosted their target price on Gilead Sciences from $116.00 to $126.00 and gave the stock a "buy" rating in a research note on Wednesday, March 5th. Cantor Fitzgerald began coverage on shares of Gilead Sciences in a research note on Tuesday, April 22nd. They set an "overweight" rating and a $125.00 target price on the stock. Royal Bank of Canada increased their price target on Gilead Sciences from $84.00 to $90.00 and gave the company a "sector perform" rating in a research note on Wednesday, February 12th. Needham & Company LLC restated a "hold" rating on shares of Gilead Sciences in a research report on Wednesday, May 21st. Finally, Morgan Stanley boosted their price target on Gilead Sciences from $130.00 to $135.00 and gave the stock an "overweight" rating in a report on Friday, April 25th. Nine analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $110.55.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.